The trial you cited tests Apixaban for prevention of a second cardiovascular event—not as a treatment for a current episode of ACS. Lacking FIIa inhibition, the oral FXa inhibitors are better suited to the former indication than the latter.
>Dabigatran RE-DEEM trial is 6 month treatment. I assume that Momenta's drug [M118] is in hospital treatment since it is IV - so do you consider the two drugs competitors?<
They are loose competitors: Dabigatran is preferable for chronic use by virtue of being a pill, but M118—if it works as advertised—will be better in acute settings. Regards, Dew
Market Data 
Markets 
AI
